Laure Peyro‐Saint‐Paul

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul et al. · EClinicalMedicine · 2021 · 66 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France

Ludivine Demessine, Laure Peyro‐Saint‐Paul, Edward M. Gardner et al. · Open Forum Infectious Diseases · 2019 · 53 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study

Laure Peyro‐Saint‐Paul, Christian Créveuil, Olivier Heinzlef et al. · Journal of the Neurological Sciences · 2016 · 46 citations

Medicine, Neurology, Pharmacology +17

Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis

Charles Dolladille, Basile Chrétien, Laure Peyro‐Saint‐Paul et al. · Neurotherapeutics · 2021 · 35 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case–control study in the French Pharmacovigilance Database

Laure Peyro‐Saint‐Paul, Paul Besnier, Ludivine Demessine et al. · Journal of Antimicrobial Chemotherapy · 2019 · 26 citations

Pharmacy, Pharmacology, Pharmacotherapy +17